Development of Fluorescent Glioma in Rats under Pharmacological Modulation of Beta2-Adrenergic Receptor
This study shows the role of adrenergic mechanisms in the development of fluorescent glioma in rats and the impairment of the blood-brain barrier (BBB) permeability. The results demonstrate that the progression of glioma was accompanied by a gradual increase in the BBB permeability and an increased expression of vascular beta2-adrenoreceptors (B2-AR). The pharmacological blockade of B2-AR reduced the degree of BBB disruption, the migration of cancer cells and increased the survival of animals. Our data support the idea that blockade of B2-AP may be a new therapeutic strategy for the treatment of glioma and the prevention of metastases.
1. Wohrer A., Waldhor T., Heinzl H., Hackl M., Feichtinger J., Gruber-Mosenbacher. The Austrian Brain Tumour Registry : a cooperative way to establish a populationbased brain tumour registry // J. of Neuro-Oncology. 2009. Vol. 95, № 3. P. 401–411.
2. Jovcevska I., Kocevar N., Komel R. Glioma and glioblastoma-how much do we (not) know? // Molec. and Clin. Oncology. 2013. Vol. 1, № 6. P. 935–941.
3. Li R., Chen X., You Y., Wang X., Liu Y., Hu Q., Yan W. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics // Oncotarget. 2015. Vol. 6, № 31. P. 30968.
4. Watkins S., Robel S., Kimbrough I. F., Robert S. M., Ellis-Davies G., Sontheimer H. Disruption of astrocytevascular coupling and the blood-brain barrier by invading glioma cells // Nature Commun. 2014. Vol. 5. P. 4196.
5. Dvorak H. F. How tumors make bad blood vessels and stroma // The Amer. J. of Pathology. 2003. Vol. 162, № 6. P. 1747.
6. Cole S. W., Nagaraja A. S., Lutgendorf S. K., Green P. A., Sood A. K. Sympathetic nervous system regulation of the tumour microenvironment // Nat. Rev. Cancer. 2015. Vol. 15, № 9. P. 563.
7. Qiao G., Chen M., Bucsek M. J., Repasky E. A., Hylander B. L. Adrenergic signaling : a targetable checkpoint limiting development of the anti-tumor immune response // Frontiers in Immunology. 2018. Vol. 9. P. 164.
8. Eldeeb B. B., Hammond E. M., Worthington D. J., Mann J. R. Urinary catecholamines and their metabolites in management of neuroblastoma // Pediatric Hematology and Oncology. 1988. Vol. 5, № 3. P. 229–237.
9. De Giorgi V., Grazzini M., Gandini S., Benemei S., Lotti T., Marchionni N., Geppetti P. Treatment with ?-blockers and reduced disease progression in patients with thick melanoma // Arch. of Internal Med. 2011. Vol. 171, № 8. P. 779–781.
10. Nguy?n L. T. H. The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment : possible genetic and cellsignaling mechanisms // Cancer Manag. and Res. 2012. Vol. 4. P. 431.
11. Song Q., Ji Q., Li Q. The role and mechanism of ?-arrestins in cancer invasion and metastasis // Intern. J. of Molecular Med. 2018. Vol. 41, № 2. P. 631–639.
12. Hoffmann A., Bredno J., Wendland M., Derugin N., Ohara P., Wintermark M. High and Low molecular weight fl uorescein Isothiocyanate (FITC)–dextrans to assess blood-brain barrier disruption : Technical considerations // Transl. Stroke Res. 2011. Vol. 2, № 1. P. 106–111.